179 related articles for article (PubMed ID: 7641752)
21. Positron emission tomography for detection and staging of malignant lymphoma.
Buchmann I; Moog F; Schirrmeister H; Reske SN
Recent Results Cancer Res; 2000; 156():78-89. PubMed ID: 10802866
[TBL] [Abstract][Full Text] [Related]
22. Tc-99m MIBI scintigraphy in patients with lung cancer. Comparison with CT and fluorine-18 FDG PET imaging.
Wang H; Maurea S; Mainolfi C; Fiore F; Gravina A; Panico MR; Bazzicalupo L; Salvatore M
Clin Nucl Med; 1997 Apr; 22(4):243-9. PubMed ID: 9099482
[TBL] [Abstract][Full Text] [Related]
23. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma.
Delbeke D; Stroobants S; de Kerviler E; Gisselbrecht C; Meignan M; Conti PS
Oncologist; 2009; 14 Suppl 2():30-40. PubMed ID: 19819922
[TBL] [Abstract][Full Text] [Related]
24. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma.
de Wit M; Bumann D; Beyer W; Herbst K; Clausen M; Hossfeld DK
Ann Oncol; 1997; 8 Suppl 1():57-60. PubMed ID: 9187431
[TBL] [Abstract][Full Text] [Related]
25. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
[TBL] [Abstract][Full Text] [Related]
26. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis.
Okada J; Yoshikawa K; Imazeki K; Minoshima S; Uno K; Itami J; Kuyama J; Maruno H; Arimizu N
J Nucl Med; 1991 Apr; 32(4):686-91. PubMed ID: 2013808
[TBL] [Abstract][Full Text] [Related]
27. [Positron-emission tomography with fluorine-18-deoxyglucose in the staging and control of patients with lymphoma. Comparison with clinico-radiologic assessment].
Mainolfi C; Maurea S; Varrella P; Alaia C; Imparato C; Alfano B; Abate G; Bazzicalupo L
Radiol Med; 1998; 95(1-2):98-104. PubMed ID: 9636735
[TBL] [Abstract][Full Text] [Related]
28. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose.
Römer W; Hanauske AR; Ziegler S; Thödtmann R; Weber W; Fuchs C; Enne W; Herz M; Nerl C; Garbrecht M; Schwaiger M
Blood; 1998 Jun; 91(12):4464-71. PubMed ID: 9616140
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease.
Spaepen K; Mortelmans L
Q J Nucl Med; 2001 Sep; 45(3):269-73. PubMed ID: 11788819
[TBL] [Abstract][Full Text] [Related]
30. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management.
Montravers F; McNamara D; Landman-Parker J; Grahek D; Kerrou K; Younsi N; Wioland M; Leverger G; Talbot JN
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1155-65. PubMed ID: 12192560
[TBL] [Abstract][Full Text] [Related]
31. 11C-acetate PET imaging of lung cancer: comparison with 18F-FDG PET and 99mTc-MIBI SPET.
Higashi K; Ueda Y; Matsunari I; Kodama Y; Ikeda R; Miura K; Taki S; Higuchi T; Tonami H; Yamamoto I
Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):13-21. PubMed ID: 14574513
[TBL] [Abstract][Full Text] [Related]
32. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma.
Cremerius U; Fabry U; Neuerburg J; Zimny M; Osieka R; Buell U
Nucl Med Commun; 1998 Nov; 19(11):1055-63. PubMed ID: 9861622
[TBL] [Abstract][Full Text] [Related]
33. Early response monitoring in malignant lymphoma using fluorine-18 fluorodeoxyglucose single-photon emission tomography.
Hoekstra OS; van Lingen A; Ossenkoppele GJ; Golding R; Teule GJ
Eur J Nucl Med; 1993 Dec; 20(12):1214-7. PubMed ID: 8299657
[TBL] [Abstract][Full Text] [Related]
34. Comparing 18-fluoro-2-deoxyglucose positron emission tomography with a combination of technetium 99m tetrofosmin single photon emission computed tomography and computed tomography to detect recurrent or persistent nasopharyngeal carcinomas after radiotherapy.
Kao CH; Tsai SC; Wang JJ; Ho YJ; Yen RF; Ho ST
Cancer; 2001 Jul; 92(2):434-9. PubMed ID: 11466699
[TBL] [Abstract][Full Text] [Related]
35. FDG-PET for the evaluation of tumor viability after anticancer therapy.
Okada J; Oonishi H; Yoshikawa K; Imaseki K; Uno K; Itami J; Arimizu N
Ann Nucl Med; 1994 May; 8(2):109-13. PubMed ID: 8074956
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma.
Naumann R; Vaic A; Beuthien-Baumann B; Bredow J; Kropp J; Kittner T; Franke WG; Ehninger G
Br J Haematol; 2001 Dec; 115(4):793-800. PubMed ID: 11843811
[TBL] [Abstract][Full Text] [Related]
37. [Current status of nuclear medicine. Clinical application of FDG-PET for cancer diagnosis. Malignant lymphoma].
Higuchi T
Nihon Igaku Hoshasen Gakkai Zasshi; 2002 May; 62(6):278-83. PubMed ID: 12073634
[TBL] [Abstract][Full Text] [Related]
38. Fluorine-18 deoxyglucose PET for assessment of viable myocardium in perfusion defects in 99mTc-MIBI SPET: a comparative study in patients with coronary artery disease.
Altehoefer C; Kaiser HJ; Dörr R; Feinendegen C; Beilin I; Uebis R; Buell U
Eur J Nucl Med; 1992; 19(5):334-42. PubMed ID: 1612095
[TBL] [Abstract][Full Text] [Related]
39. (18)F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging.
Lopci E; Burnelli R; Ambrosini V; Nanni C; Castellucci P; Biassoni L; Rubello D; Fanti S
Cancer Biother Radiopharm; 2008 Dec; 23(6):681-90. PubMed ID: 19111053
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of FDG-PET in malignant lymphoma.
Becherer A; Jaeger U; Szabo M; Kletter K
Q J Nucl Med; 2003 Mar; 47(1):14-21. PubMed ID: 12714950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
